ADVENTRX to Present at Annual Euro-Biotech Forum.SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange :ANX ANX Annex ANX Adventrx Pharmaceuticals (San Diego, CA) ANX Automotive Network Exchange (AIAG) ANX Advanced Network Exchange ANX Ascending Node Crossing (satellites) ) announced today that Brian M. Culley, vice president of business development, will present a corporate overview at the 13th Annual Euro-Biotech Forum on June 29 at 2:45 p.m. Central European Summer Time Central European Summer Time (CEST) is one of the names of UTC+2 time zone, 2 hours ahead of Coordinated Universal Time. It is used as a summer daylight saving time in most European and some North African countries. During the winter, Central European Time (UTC+1) is used. . The Euro-Biotech Forum is an industry partnering meeting for American and European life science companies. The conference takes place June 27-29, 2006, at the Westin Paris. More information about the conference can be found on the conference Web site at http://www.eurobiotechforum.com. About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing treatments for cancer and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration. bi·o·a·vail·a·bil·i·ty n. and resistance. More information can be found on the Company's Web site at www.adventrx.com. Forward-Looking Statement This press release contains forward-looking statements, within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, regarding ADVENTRX. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last annual report on Form 10-K and its Quarterly Reports on Form 10-Q, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions to forward-looking statements to reflect events or circumstances which occur after the date hereof. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion